After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Brookline starts Caladrius Biosciences at buy; PT $7
Brookline Capital Markets initiated coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and a price target of $7. The stock was quoted at $2.05, up 12 cents, at mid-day on May 22...
Study with Daxor BVA-100 published in Circulation
Blood volume outcome data has been published in the American Heart Association journal, Circulation, utilizing Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device to determine the primary endpoint...
Raymond James adds Profound Medical to “analyst current favorite”
Raymond James added Profound Medical (TSX:PRN; NASDAQ:PROF) as an “analyst current favorite,” maintaining a “strong buy” recommendation, after AstraZeneca and Merck received FDA approval for their PARP inhibitor drug...
Cidara doses first patient in Phase 3 rezafungin trial
Cidara Therapeutics (NASDAQ:CDTX) dosed the first patient in its Phase 3 trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. The...
Passage Bio gets rare pediatric disease designation for gangliosidosis
Passage Bio’s (NASDAQ:PASG) PGBM01 received FDA rare pediatric disease designation for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene impair...
Kadmon reports positive topline results from pivotal GvHD trial
Kadmon Holdings (NYSE:KDMN) reported positive topline results from its pivotal trial of KD025 (belumosudil) in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of...
Imagin Medical receives functional i/Blue Imaging Systems
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) received functional i/Blue systems from its contract design and development firm, Optel, which will be used to conduct in...
Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431
Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the fourth dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 225 mg dosing level to be safe and...
Bee Vectoring in cranberry trials with natural pesticide
Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) plans to conduct trials of its natural precision agriculture system on cranberries in Massachusetts and New Jersey, two major cranberry growing...
Maxim ups Co-Diagnostics to buy; PT $30
Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...
PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine
Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...
Brookline starts Cyclacel Pharma at buy; PT $22
Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...
Just a few of the companies we’ve highlighted along the way
